Daclatasvir

Bezeichnung:Daclatasvir

CAS-Nr1009119-64-5

Englisch Name:Daclatasvir

CBNumberCB52515028

SummenformelC40H50N8O6

Molgewicht738.88

MOL-Datei1009119-64-5.mol

Daclatasvir physikalisch-chemischer Eigenschaften

Schmelzpunkt	>155oC (dec.)
Siedepunkt	1071.2±65.0 °C(Predicted)
Dichte	1.249
storage temp.	Refrigerator
Löslichkeit	Aqueous Acid (Slightly), Chloroform (Sparingly), DMSO (Sparingly), Methanol (Sparingly)
Aggregatzustand	Solid
pka	10.92±0.46(Predicted)
Farbe	White to Dark Yellow

Sicherheit

S-Sätze:	24/25
HS Code	29332900

Gefahreninformationscode (GHS)

Daclatasvir Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden
Daclatasvir, inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV).
Definition
ChEBI: Daclatasvir is a member of the class of biphenyls that is a potent inhibitor of nonstructural protein 5A and is used (as its hydrochloride salt) for treatment of hepatitis C. It has a role as a nonstructural protein 5A inhibitor and an antiviral drug. It is a member of biphenyls, a member of imidazoles, a carbamate ester, a carboxamide and a valine derivative. It is a conjugate base of a daclatasvir(2+).
Mechanism of action
Daclatasvir is an inhibitor of NS5A, a phosphoprotein that plays an important role in hepatitis C replication.Daclatasvir reduces serum HCV RNA levels. It disrupts HCV replication by inhibiting viral RNA replication and viral assembly and by inhibiting phosphorylation of NS4A, thereby inhibiting the formation and activation of the HCV replication complex.
Clinical Use
Inhibitor of nonstructural protein 5A (NS5A):
Treatment of chronic hepatitis C infection in combination with other medication
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Aldesleukin: avoid concomitant use.
Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
Stoffwechsel
Dacarbazine (DTIC) is assumed to be inactive
Dacarbazine is extensively metabolised in the liver Dacarbazine is extensively metabolised in the liver by the cytochrome P450 isoenzymes CYP1A2 and CYP2E1 (and possibly in the tissues by CYP1A1) to its active metabolite 5-(3-methyl-triazen-1-yl)- imidazole-4-carboxamide (MTIC), which spontaneously decomposes to the major metabolite 5-amino-imidazole- 4-carboxamide (AIC). About half of a dose is excreted in the urine by tubular secretion; 50% as unchanged DTIC and approximately 50% as AIC.

Daclatasvir Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

1009119-64-5, Daclatasvir Verwandte Suche:

Send Inquriy